Attached files

file filename
EX-99.1 - SUNWIN INTERNATIONAL NEUTRACEUTICALS, INC. MARCH 29, 2011 PRESS RELEASE - SUNWIN STEVIA INTERNATIONAL, INC.suwnex.htm
 



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

 
FORM 8-K
 
 
CURRENT REPORT
 
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
 
Date of Report (Date of earliest event reported)                                                                                     March 29, 2011
 

SUNWIN INTERNATIONAL NEUTRACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Nevada
000-53595
56-2416925
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

6 Shengwang Avenue, Qufu, Shandong China
273100
(Address of principal executive offices)
(Zip Code)

Registrant's telephone number, including area code
(86) 537-4424999

not applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



 
 
 
 

 


Item 7.01                      Regulation FD Disclosure.

On March 29, 2011 Sunwin International Neutraceuticals, Inc. issued a press release announcing the receipt of the ISO 22000, ISO 9001:2008 and HACCP Integrated Systems Certifications.  A copy of the press release is furnished as Exhibit 99.1 to this report.

Pursuant to General Instruction B.2 of Form 8-K, the information in this Item 7.01 of Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise be subject to the liabilities of that section, nor is it incorporated by reference into any filing of Sunwin International Neutraceuticals, Inc. under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01                      Financial Statements and Exhibits.

(d)           Exhibits

99.1         Press release dated March 29, 2011.

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
SUNWIN INTERNATIONAL NEUTRACEUTICALS,  INC.
   
Date:  March 29, 2011
By:  /s/ Dongdong Lin
 
        Dongdong Lin,
        Chief Executive Officer